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Abstract 
Aims: Methionine restriction (MR) and hepatic protein tyrosine phosphatase 1B (PTP1B) knockdown 
both improve hepatic insulin sensitivity by targeting different proteins within the insulin signaling 
pathway, as well as diminishing hepatic triglyceride content through decreasing hepatic lipogenesis. 
We hypothesised that a combined approach of hepatic PTP1B inhibition and methionine restriction 
could lead to a synergistic effect on improvements in glucose homeostasis and lipid metabolism. 
Methods: Male and female hepatic-PTP1B knockout (Alb-Ptp1b
-/-
) and control wild-type (Ptp1b
fl/fl
) 
mice were maintained on control diet (0.86% methionine) or MR diet (0.172% methionine) for 8 
weeks. Body weight and food intake were recorded and physiological tests for whole-body glucose 
homeostasis were performed. Serum and tissues were analysed biochemically. 
Results: MR decreased body weight and increased food intake in Ptp1b
fl/fl 
mice as expected, without 
changing PTP1B protein expression levels or activity. In females, MR treatment alone improved 
glucose tolerance in Ptp1b
fl/fl
 mice, which was further amplified with hepatic-PTP1B deficiency.  
However, other markers of glucose homeostasis were similar between MR-fed groups. In males, MR 
improved glucose homeostasis in both, Alb-Ptp1b
-/-
 and wild-type Ptp1b
fl/fl
 mice to a similar extent.  
Hepatic-PTP1B inhibition in combination with MR could not further enhance insulin-stimulated 
hepatic protein kinase B/Akt phosphorylation compared to MR treatment alone and therefore led to no 
further increase in hepatic insulin signaling. The combined treatment did not further improve lipid 
metabolism relative to MR diet alone. 
Conclusions: Methionine restriction improves glucose and lipid homeostasis; however, adding hepatic 
PTP1B inhibition to MR is unlikely to yield any additional protective effects.  
 
Keywords:  
Glucose. Insulin. Liver. Diabetes. 
 
1. Introduction 
Insulin resistance and type 2 diabetes are increasing in prevalence worldwide [1]. Type 2 diabetes is 
preceded by insulin resistance; characterised by decreased insulin-dependent glucose uptake into 
peripheral tissues and inadequate suppression of hepatic glucose production, resulting in 
hyperglycemia [2]. Insulin secretion is initially increased to counteract this; however, type 2 diabetes 
occurs when the pancreatic beta cells can no longer compensate for the increased demand for insulin 
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secretion due to loss of beta cell mass [3]. The mechanism(s) behind insulin resistance remain unclear 
[4, 5] although, it is generally agreed that impaired post-insulin receptor (IR) signal transduction is 
involved [6]. 
Insulin signaling is activated when insulin binds to the IR, leading to autophosphorylation of the IR 
and the ability of it to phosphorylate target substrates including the IRS proteins [6]. Further 
downstream, protein kinase B (PKB/Akt) is phosphorylated to promote glucose uptake [6]. PKB/Akt 
also leads to the activation of the mechanistic target of rapamycin complex 1 (mTORC1), which 
stimulates protein synthesis through activating p70 ribosomal S6 kinase (p70S6K) and its downstream 
target; ribosomal protein S6 (S6) [6]. Insulin resistance is also linked to the accumulation of hepatic 
lipids [2], as occurs in non-alcoholic fatty liver disease (NAFLD). NAFLD, which affects 20-35% of 
the population, is characterised by excess lipid stores within the liver in the absence of alcohol 
consumption [7]. 
Methionine restriction (MR) is a dietary modification that involves reducing the amount of the 
essential amino acid, methionine, to 5-times lower levels than the control diet (0.86% to 0.172%). In 
comparison to control-fed rodents, MR limits weight gain and diminishes accretion of adiposity, 
despite increased food intake [8-17] due to stimulation of nonshivering thermogenesis in adipose 
tissue, leading to elevated energy expenditure [10, 16]. It also improves whole-body glucose 
homeostasis [8, 11, 12, 17] and insulin signaling in peripheral tissues [11, 17].The enhancement of 
insulin signaling in the liver by MR is a direct effect of secondarily limiting the availability of the 
cysteine needed for synthesis of hepatic glutathione (GSH) [17-19]. GSH is an essential co-factor for 
GSH peroxidase which activates phosphatase and tensin homologue (PTEN) [20] a phosphatase 
responsible for the dephosphorylation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [6]. The 
reduction in hepatic glutathione by MR slows the reactivation of PTEN, which increases PIP3 levels 
and amplifies downstream PKB/Akt phosphorylation [17]. As MR targets PIP3, it has no effect on 
upstream components such as levels of IR or IRS1 phosphorylation [17]. MR also decreases hepatic 
lipogenesis through targeted effects on lipogenic gene expression, leading to decreased hepatic 
triglyceride levels [8, 11, 14, 21, 22]. For example, a 16-week MR intervention in human subjects 
with metabolic syndrome produced a significant reduction in hepatic lipid content [23]. 
Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed non-receptor tyrosine 
phosphatase which negatively regulates leptin and insulin signaling [2, 24-27]. Due to PTP1B 
downregulating these signaling pathways, whole-body Ptp1b knockout mice are lean with enhanced 
insulin sensitivity [28, 29]. Within the insulin signaling pathway PTP1B directly targets the IR and 
IRS1 in muscle and liver, whereas it is not a negative regulator of these proteins in adipose tissue [2, 
27, 30]. Liver-specific knockout of Ptp1b from birth results in improved glucose homeostasis caused 
by enhanced hepatic insulin signaling [2] and tamoxifen-inducible hepatic Ptp1b knockdown in adult 
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mice leads to the reversal of high-fat diet-induced glucose intolerance [31]. Hepatic PTP1B inhibition 
also lowers hepatic triacylglycerol storage [31] and lipogenic gene expression [2]. Pharmaceutical 
companies have been developing PTP1B inhibitors as insulin-sensitizers, and currently the inhibitor 
trodusquemine is in phase 2 clinical trials [32]. Furthermore, an antisense oligonucleotide targeting 
PTP1B, developed by ISIS Pharmaceuticals also improved insulin sensitivity in monkeys [33]. 
 
Due to hepatic PTP1B directly targeting IR and IRS1 within the insulin signaling pathway and MR 
acting downstream to amplify PKB/Akt phosphorylation; the aim of this study was to determine if 
there was a synergistic effect of a dual-therapy on hepatic insulin signaling and whole-body glucose 
homeostasis.  
 
2. Materials and Methods 
 
2.1. Ethics statement 
All animal studies were approved by the University of Aberdeen Ethics Review Board and completed 
under a project licence (PPL60/3951) approved by the UK Home Office under the Animals (Scientific 
Procedures) Act 1986. 
 
2.2. Animals  
Albumin-Cre mice  are crossed with Ptp1b
fl/fl
 mice resulting in Alb-Ptp1b
-/-
 mice with hepatocyte-
specific deletion of PTP1B from birth. Alb-Ptp1b
-/-
 and Ptp1b
fl/fl 
mice were previously described [2]. 
Female (5-7 mo old) and male (9-12 mo old) mice studied were on a mixed 129Sv/C57BL6 
background. Mice were individually caged and maintained on a 12h-h light/dark cycle at 22-24 °C 
with free access to food and water. Mice were maintained on a control diet (0.86% methionine) 
(Dyets, Bethlehem, PA, USA) for 2 weeks. After randomising for body weight, half (females; n=8, 
males; n=5) of the control Ptp1b
fl/fl 
mice were placed on control diet and half (females; n=8, males; 
n=5) on to MR diet (0.172% methionine) (Dyets, Bethlehem, PA, USA). All Alb-Ptp1b
-/-
 mice were 
placed on MR diet. Glutamic acid content of the MR diet was adjusted to produce equal amounts of 
total amino acids in both diets. Body weight and food intake were recorded every 3 days. After 8 
weeks on the diet, the mice were fasted for 5-hours before being i.p. injected with saline or insulin 
(females 0.8mU/g body weight, males 10mU/g body weight). Cervical dislocation was performed 10 
minutes post-injection and tissues were immediately frozen in liquid nitrogen.
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2.3. PTP1B activity assay 
PTP1B activity was measured as described previously [31]. Briefly, liver lysates were prepared in 
PTP lysis buffer (130 mmol/l NaCl, 20 mmol/l TRIS (pH 7.5), 5 mmol/l EDTA, 1% Triton X-100 
(v/v), 0.5% Nonidet P-40 (v/v)-containing protease inhibitors). PTP1B protein was 
immunoprecipitated using PTP1B antibody (Millipore, Watford, UK) and protein G-sepharose beads. 
The reaction was performed using pp60c-src C-terminal phosphoregulatory peptide (Enzo Life 
Sciences, Exeter, UK) for 30 minutes at 30°C with constant shaking. The amount of phosphate 
produced was measured by absorbance at 620 nm and used to indicate level of PTP1B protein 
activity. 
 
2.4. Immunoblotting 
Frozen liver lysates were prepared in RIPA buffer as described previously [27]. Proteins were 
separated by 4–12% SDS-PAGE and transferred to nitrocellulose membranes. Immunoblots were 
performed using antibodies from Cell Signaling Technology (Cell Signaling by NEB, Hitchin, UK) 
(unless stated otherwise) against PTP1B (Millipore, Watford, UK); phospho-S6 (s235/236); total S6; 
phospho-Akt/PKB (s473); phospho-IR (tyr1163/1163) (Invitrogen, Paisley, UK); IR-β (Santa Cruz, 
Dallas, TX, USA); total Akt/PKB (Santa Cruz, Dallas, TX, USA) and Glyceraldehyde 3-phosphate 
dehydrogenase  (GAPDH)  (Santa Cruz, Dallas, TX, USA). Proteins were visualized using enhanced 
chemiluminescence and quantified by densitometry scanning (Image J) or Bio-1D software (Peqlab, 
Sarisbury Green, UK). 
     
2.5. Serum analysis 
Six-weeks after beginning MR or control diet, tail vein blood samples were taken following a 5-h fast. 
All serum measurements were made on these. Serum glucose (glucose oxidase, Thermo Scientific, 
Waltham, MA, USA) and serum triacylglycerol (Sentinel Diagnostics, Milan, Italy) were measured 
using appropriate kits. Serum insulin and leptin (CrystalChem, Downers Grove, IL, USA) were 
determined by ELISA. Serum NEFAs were measured using a kit (Wako Chemicals, Richmond, VA, 
USA). Assays were measured using a Spectramax Plus 384 spectrophotometer (Molecular Devices, 
Sunnyvale, CA, USA).   
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2.6. Glucose and pyruvate tolerance tests 
Glucose tolerance tests were performed after 5-weeks of dietary treatment. Mice were i.p. injected, 
following a 5-h fast, with 2 mg/g BW glucose. For pyruvate tolerance tests, performed after 7-weeks 
of dietary treatment, mice were injected with 2 mg/g pyruvate. Tail blood glucose measurements 
using glucometers (AlphaTRAK, Berkshire, UK) were taken immediately before and at 15, 30, 60 and 
120 min post-injection. 
 
2.7. Gene expression analysis  
Total RNA was isolated from mouse liver using peqGOLD TriFast (Peqlab, Sarisbury Green, UK). 
First strand cDNA was synthesized from 1 µg of total RNA using bioscript cDNA synthesis kit 
(Bioline, London, UK), oligo (dT) 18 primers and random hexamer primers.  Quantitative PCR 
(qPCR) was used to amplify target genes using GoTaq qPCR Master Mix (Promega, Southampton, 
UK) and gene-specific primers on the Roche LightCycler® 480 System (Roche Diagnostics, Burgess 
Hill, UK). Relative gene expression was calculated using the Pfaffl method [34] and normalised to the 
reference gene hypoxanthine-guanine phosphoribosyltransferase (Hprt). 
 
2.8. Data analysis 
 Data are expressed as mean ± SEM. Statistical analyses were performed using repeated measures 
two-way ANOVA with Bonferroni multiple comparison post-tests or one-way ANOVA with Tukey’s 
multiple comparison post-tests, as appropriate. P < 0.05 was considered statistically significant. 
GraphPad Prism 5 statistical software (GraphPad Software, Inc., San Diego, CA, USA) was used for 
analyses. 
 
3. Results 
 
3.1. MR does not affect hepatic PTP1B protein or activity levels 
To be able to assess if any further improvements in glucose or lipid homeostasis occur when adding 
hepatic PTP1B inhibition to MR, it was first important to ensure that MR was not affecting hepatic 
PTP1B or activity levels. Hepatic PTP1B protein levels were significantly decreased by 32% in 
female MR-fed Alb-Ptp1b
-/-
 mice relative to female MR-fed Ptp1b
fl/fl 
mice (Fig. 1A and B). Hepatic 
PTP1B protein activity was also decreased by 40% in female MR-fed Alb-Ptp1b
-/-
 mice compared to 
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female MR-fed Ptp1b
fl/fl
 mice (Fig. 1C). MR diet in Ptp1b
fl/fl 
female mice had no effect on hepatic 
PTP1B protein or activity levels, compared to control-fed Ptp1b
fl/fl
 mice (Fig. 1A, B and C). 
 
3.2. MR decreases body weight in both Alb-Ptp1b
-/-
 and Ptp1b
fl/fl 
mice. 
Both female and male mice on MR (Ptp1b
fl/fl 
and Alb-Ptp1b
-/-
) exhibited decreased body weight 
throughout the course of the study compared to control-fed Ptp1b
fl/fl 
mice (Fig. 2A and B). Female 
MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice had significantly lower body weight relative to 
control-fed Ptp1b
fl/fl
 mice from days 22-43 of the dietary treatment (Fig. 2A). MR-fed Ptp1b
fl/fl
 and 
MR-fed Alb-Ptp1b
-/-
 mice did not differ in body weight levels throughout the duration of the study in 
both female and male mice (Fig. 2A and B). Food intake (g/ g BW/ day) was significantly increased 
in female and male MR-fed Alb-Ptp1b
-/-
 mice and also elevated in MR-fed Ptp1b
fl/fl
 mice compared to 
control-fed Ptp1b
fl/fl
 mice (Fig. 2C and D) There were no differences in food intake in either female or 
male groups between MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice (Fig. 2C and D). 
 
3.3. MR and hepatic PTP1B knockdown increase hepatic insulin signaling but do not act 
synergistically. 
MR alone had no effect on levels of phosphorylation of the IR (MR-fed Ptp1b
fl/fl 
vs. control-fed 
Ptp1b
fl/fl
 mice) (Fig. 3A and C). MR-fed Alb-Ptp1b
-/-
 mice did increase levels of phosphorylation of 
the IR compared to both MR-fed Ptp1b
fl/fl
 and control-fed Ptp1b
fl/fl
 mice (Fig. 3A and C). Both groups 
on MR (Ptp1b
fl/fl 
and Alb-Ptp1b
-/-
) had increased levels of phosphorylation of PKB/Akt and an 
increased ratio of phosphorylated to total PKB/Akt relative to control-fed Ptp1b
fl/fl
 mice (Fig. 3A, B 
and D). The two groups fed MR diet (Ptp1b
fl/fl 
and Alb-Ptp1b
-/-
) did not differ from each other in 
levels of phosphorylation of PKB/Akt or ratio of phosphorylated to total PKB/Akt (Fig. 3A, B and D). 
There were no differences for diet or genotype on levels of phosphorylated or total S6 (Fig. 3A, B and 
E). 
 
3.4. Hepatic PTP1B knockdown does not further improve glucose homeostasis except in levels of 
glucose tolerance in females. 
In female mice, MR significantly increased glucose tolerance in Ptp1b
fl/fl 
mice relative to control-fed 
Ptp1b
fl/fl
 mice (Fig. 4A). Female MR-fed Alb-Ptp1b
-/-
 mice improved glucose tolerance even further 
and significantly enhanced glucose tolerance compared to control-fed Ptp1b
fl/fl
 mice and MR-fed 
Ptp1b
fl/fl
 mice (Fig. 4A). In males, MR-fed Ptp1b
fl/fl
 mice had an improved response to a glucose 
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challenge compared to control-fed Ptp1b
fl/fl
 mice. MR-fed Alb-Ptp1b
-/-
 mice significantly enhanced 
glucose tolerance compared to control-fed Ptp1b
fl/fl
 mice; however, there was no additional 
improvement in glucose tolerance between MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice (Fig. 4B). 
To examine if there was any additional effect of supplementing MR with hepatic PTP1B knockdown 
on suppression of hepatic gluconeogenesis, we performed a pyruvate-tolerance test (PTT) in female 
mice (Fig. 4C). MR-fed Alb-Ptp1b
-/-
 mice significantly improved and MR-fed Ptp1b
fl/fl
 mice also 
enhanced their response to a pyruvate challenge compared to control-fed Ptp1b
fl/fl
 mice; however, 
there were no additional differences between MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice (Fig. 
4C). Both MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 female mice had significantly decreased fasting 
blood glucose levels relative to control-fed Ptp1b
fl/fl
 mice (Fig. 4D). There were no additive 
differences between MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice in fasting blood glucose levels 
(Fig. 4D). In male mice, there were no differences between groups on fasting blood glucose levels 
(Fig. 4E). In both female and male mice both groups fed MR (Ptp1b
fl/fl 
and Alb-Ptp1b
-/-
) showed 
significantly lower fasting serum insulin levels relative to control-fed Ptp1b
fl/fl
 mice (Fig. 4F and G). 
Again, there was no difference between MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice for fasting 
serum insulin levels in either female or male mice (Fig. 4F and G). 
 
3.5. MR improves lipid homeostasis which is not further exacerbated by hepatic PTP1B 
knockdown  
Both MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 female mice had significantly decreased fasting serum 
leptin levels relative to control-fed Ptp1b
fl/fl
 mice (Fig. 5A). However, there were no additional 
differences between MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice in fasting serum leptin levels in 
female mice (Fig. 5A). In male mice, both MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice had lower 
fasting serum leptin levels compared to control-fed Ptp1b
fl/fl
 mice; yet again these were not additive 
(Fig. 5B). Diet and genotype had no effect on fasting serum NEFA levels or fasting serum 
triacylglycerol levels in either female or male mice (Fig. 5C, D, E and F). In female mice, both MR-
fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice had significantly decreased hepatic gene expression of 
Srebp1c and also decreased expression of other lipogenic genes, including Srebp1a and Fas relative to 
control-fed Ptp1b
fl/fl
 mice (Fig. 5G). There were no differences in levels of these hepatic lipogenic 
genes between MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 female mice (Fig. 5G). Both female MR-fed 
Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice showed reduced hepatic gluconeogenesis through decreased 
mRNA expression of Glucose-6-phosphate (G6p) relative to control-fed Ptp1b
fl/fl
 mice, but the two 
MR-fed groups (Ptp1b
fl/fl 
and Alb-Ptp1b
-/-
) did not differ from each other (Fig. 5G).  
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4. Discussion 
The increasing prevalence of metabolic syndrome demands more effective drug therapies [35]. MR 
produces many beneficial effects including reduced body mass and adiposity and improved glucose 
homeostasis [8-17]. We have shown previously that both hepatic PTP1B deletion from birth or 
knockdown in adult insulin-resistance mice protects against the development of insulin resistance and 
reverses established glucose intolerance, respectively [2, 31, 36]. These studies established 
definitively that in the liver, PTP1B deletion results in increased IR and IRS1 phosphorylation. Recent 
studies on the beneficial insulin sensitizing effects of MR diet in the liver revealed that hepatic 
PKB/Akt phosphorylation is enhanced [11, 17]. We therefore hypothesised that there could be an 
additive effect on hepatic insulin sensitivity and whole-body glucose homeostasis if MR diet is 
combined with liver PTP1B deficiency. Our study suggests that MR improves glucose homeostasis 
and lipid metabolism; however, there were no major additional therapeutic effects of the combined 
treatment.    
Hepatic PTP1B protein levels and PTP1B enzyme activity levels in female mice were decreased as 
expected in the Alb-Ptp1b
-/-
 mice. The MR-fed Alb-Ptp1b
-/-
 mice did not present a complete deletion 
of PTP1B within the liver as it has in other studies [2], but rather a 32% decrease in protein and 40% 
decrease in activity levels; however, the deletion is hepatocyte-specific and so there are other cell 
types expressing normal levels of PTP1B within the whole liver lysates used for these assays [2]. The 
level of deletion would be consistent with the physiological level of PTP1B inhibition expected to be 
achieved by inhibitor drugs and therefore the results represent applicable findings [37]. It was recently 
reported that MR limits the activity of hepatic phosphatase PTEN, and the authors found no evidence 
to suggest that PTP1B was a target of the diet [17].  Thus, it is important that we found that MR itself 
had no effect on hepatic levels of PTP1B protein or activity so that we could directly assess the utility 
of a combined treatment. 
MR causes a decrease in body weight despite elevating food intake [8-17]; however, hepatic PTP1B 
deletion has no affect on energy balance [2, 31]. The body weight loss and increased food intake 
produced by MR compared to control-fed mice was similar between genotypes and is therefore likely 
to be an effect of MR only. The study also found that MR can decrease body weight and enhance 
energy intake in mice on a new genetic background (129Sv/C57BL6), confirming findings from other 
genetic backgrounds [8, 11, 13, 16, 17]. 
In agreement with previous findings, which demonstrated that hepatic PTP1B directly targets the IR 
and IRS1 [2], Alb-Ptp1b
-/-
 mice had increased levels of phosphorylation of the IR compared to 
Ptp1b
fl/fl
 mice. MR itself caused no change in phosphorylation levels of hepatic IR, consistent with 
recent findings which demonstrated that MR limits degradation of PIP3, leading to enhanced 
downstream activation and phosphorylation of PKB/Akt, which we also found in this study [17]. It 
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was hypothesised that hepatic PTP1B inhibition in combination with MR would act additionally on 
phosphorylation of PKB/Akt; however, this was similar between the combined treatment and MR 
alone. It may be that MR-treatment alone already leads to maximally increased PKB/Akt 
phosphorylation so that increased signaling upstream of PKB/Akt at the level of IR/IRS1 (achieved by 
PTP1B inhibition) cannot lead to further improvements. This may suggest that this is the major mode 
of action that MR plays in the liver.   
Consistent with MR’s known effects to improve glucose homeostasis, MR in both groups improved 
glucose tolerance and lowered blood glucose and serum insulin levels compared to control-fed 
Ptp1b
fl/fl
 mice [8, 9, 11, 12, 17]. This was further improved by PTP1B knockdown in a glucose 
tolerance test in female mice; however, there was no additional effect present in the male mice. The 
reason behind the additional improvements in glucose tolerance in female mice that were not present 
in male mice could be due to the male mice being older and therefore naturally more glucose 
intolerant compared to the females [38]. Furthermore, we cannot exclude the possibility that sex 
hormones such as estrogen play an additional beneficial and protective role in the MR-fed Alb-Ptp1b
-/-
 
mice [39]. Blood glucose levels in a pyruvate tolerance test and fasting blood glucose and serum 
insulin levels were similarly lowered between female MR-fed Ptp1b
fl/fl
 and MR-fed Alb-Ptp1b
-/-
 mice. 
There was also no further improvement by inhibition of hepatic-PTP1B in the male mice. Since the 
combined-treatment of MR and hepatic PTP1B inhibition did not result in additional enhancement in 
hepatic insulin signaling, or suppression of blood glucose, serum insulin and hepatic gluconeogenic 
genes, this suggests that MR alone is sufficient to observe these beneficial effects. 
Interestingly, the combined MR and hepatic PTP1B inhibition treatment produced no further 
improvements in lipid metabolism to MR alone, with fasting serum leptin levels being the same 
between the MR-fed groups, but both lower than Ptp1b
fl/fl
 control-fed mice. Due to no additional 
effect of hepatic PTP1B knockdown this finding is most likely due to MR decreasing adiposity levels 
[8-12, 14-16]. MR decreases hepatic lipogenesis [9-11, 14, 21, 40] and hepatic PTP1B deletion has 
also been shown to produce similar findings [2]; but again, supplementing MR with hepatic PTP1B 
inhibition led to no further effects on hepatic lipogenesis. This could be due to MR inhibiting 
lipogenic gene expression by such a substantial amount that hepatic PTP1B inhibition cannot decrease 
gene expression further, or it is possible that there is a common mechanism behind these two 
treatments. Both MR-fed groups expressed decreased hepatic gluconeogenesis compared to control-
fed Ptp1b
fl/fl
 mice, although adding hepatic PTP1B inhibition to MR led to no further reduction. This 
corresponds with the same level of insulin-stimulated PKB/Akt activation in both MR-fed groups, as 
gluconeogenesis is down-regulated downstream of PKB/Akt [6]. MR was shown in a recent study to 
inhibit hepatic gluconeogenesis [11] and hepatic PTP1B knockdown also decreases hepatic 
gluconeogenic gene expression [2, 31]. 
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In conclusion, although MR and hepatic PTP1B inhibition have separate targets in the insulin 
signaling pathway, our findings suggest that when their effects downstream converge on PKB/Akt, 
the signal is not further amplified. 
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Figure legends 
Fig. 1 Hepatic PTP1B protein and activity levels in female mice. (a) Hepatic PTP1B protein levels 
of CON
 
Ptp1b
fl/fl
 mice (n=4), MR Ptp1b
fl/fl
 (n=4) and MR Alb-Ptp1b
-/-
 (n=4). (b) Quantification of 
hepatic PTP1B protein levels in CON
 
Ptp1b
fl/fl
 mice (n=7), MR Ptp1b
fl/fl
 (n=8) and MR Alb-Ptp1b
-/-
 
(n=8). (c) Hepatic PTP1B activity levels in CON
 
Ptp1b
fl/fl 
mice (n=5), MR Ptp1b
fl/fl
 (n=6) and MR 
Alb-Ptp1b
-/-
 (n=5). Data are represented as mean ± s.e.m. White bars, CON
 
Ptp1b
fl/fl
; grey bars, MR 
Ptp1b
fl/fl
;black bars, MR Alb-Ptp1b
-/-
. Data were analysed by one-way ANOVA with Tukey's multiple 
comparison post hoc test. $ MR Alb-Ptp1b
-/-
 mice significantly different to MR Ptp1b
fl/fl
 mice 
(p<0.05). # MR Alb-Ptp1b
-/-
 mice significantly different to CON
 
Ptp1b
fl/fl 
mice (p<0.05). 
 
Fig. 2 Body weight and food intake. (a) Body weight of female CON
 
Ptp1b
fl/fl 
(n=8), MR Ptp1b
fl/fl
 
(n=8) and MR Alb-Ptp1b
-/-
 mice (n=8). (b) Body weight of male CON
 
Ptp1b
fl/fl 
(n=5), MR Ptp1b
fl/fl
 
(n=5) and MR Alb-Ptp1b
-/-
 mice (n=5). (c) Food intake of female CON
 
Ptp1b
fl/fl 
(n=5), MR Ptp1b
fl/fl
 
(n=4) and MR Alb-Ptp1b
-/-
 mice (n=7). (d) Food intake of male CON
 
Ptp1b
fl/fl 
(n=5), MR Ptp1b
fl/fl
 
(n=4) and MR Alb-Ptp1b
-/-
 mice (n=5). Data are represented as mean ± s.e.m. White circles, CON
 
Ptp1b
fl/fl 
; grey squares, MR Ptp1b
fl/fl
; black triangles, MR Alb-Ptp1b
-/-
. Data were analysed by 
repeated measures two-way ANOVA with Bonferroni multiple comparison post hoc tests.* MR Alb-
Ptp1b
-/-
 and MR Ptp1b
fl/fl
 mice significantly different to CON
 
Ptp1b
fl/fl 
mice (p<0.05). & MR Ptp1b
fl/fl
 
mice significantly different to CON
 
Ptp1b
fl/fl 
mice (p<0.05). # MR Alb-Ptp1b
-/-
 mice significantly 
different to CON
 
Ptp1b
fl/fl 
mice (p<0.05). 
 
Fig. 3 Hepatic insulin signaling in male mice. (a) Immunoblots of pIR (tyr 1162/1163), pAKT/PKB 
(Ser 473) and pS6 (ser 235/236) in insulin-stimulated CON
 
Ptp1b
fl/fl
 (n=5), MR Ptp1b
fl/fl
 (n=5) and 
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MR Alb-Ptp1b
-/-
 mice (n=5). (b) Immunoblots of IR-β, Akt and S6 in insulin-stimulated CON Ptp1bfl/fl 
(n=5), MR Ptp1b
fl/fl
 (n=5) and MR Alb-Ptp1b
-/-
 mice (n=5). (c) Quantification of pIR, IR- β and 
pIR/IR-β in CON Ptp1bfl/fl (n=5), MR Ptp1bfl/fl (n=5) and MR Alb-Ptp1b-/- mice (n=5). (d) 
Quantification of pAkt, Akt and pAkt/Akt in CON
 
Ptp1b
fl/fl 
(n=5), MR Ptp1b
fl/fl
 (n=5) and MR Alb-
Ptp1b
-/-
 mice (n=5). (e) Quantification of pS6, S6 and pS6/S6 in CON
 
Ptp1b
fl/f 
 (n=5), MR Ptp1b
fl/fl
 
(n=5) and MR Alb-Ptp1b
-/-
 mice (n=5). Phosphorylated proteins and total proteins were each 
normalised to ponceau and then ratio of phosphorylated:total calculated. S = i.p. injected with saline 
as control. Data are represented as mean ± s.e.m. White bars, CON
 
Ptp1b
fl/fl 
; grey bars, MR Ptp1b
fl/fl
; 
black bars, MR Alb-Ptp1b
-/-
. Data were analysed by one-way ANOVA with Tukey's multiple 
comparison post hoc test. 
 
Fig. 4 Glucose homeostasis. Glucose tolerance assessed by a GTT after a 5-h fast was performed on 
(a) female CON
 
Ptp1b
fl/fl 
(n=8), MR Ptp1b
fl/fl
 (n=8) and MR Alb-Ptp1b
-/-
 mice (n=8) and (b) male 
CON
 
Ptp1b
fl/fl 
(n=5), MR Ptp1b
fl/fl
 (n=5) and MR Alb-Ptp1b
-/-
 mice (n=5). (c) Pyruvate tolerance 
assessed by a PTT after a 5-h fast was performed on female CON
 
Ptp1b
fl/fl 
(n=8), MR Ptp1b
fl/fl
 (n=8) 
and MR Alb-Ptp1b
-/-
 mice (n=8). Fasting blood glucose levels were measured in (d) female CON
 
Ptp1b
fl/fl 
(n=8), MR Ptp1b
fl/fl
 (n=8) and MR Alb-Ptp1b
-/-
 mice (n=8) and (e) male CON
 
Ptp1b
fl/fl 
(n=5), 
MR Ptp1b
fl/fl
 (n=5) and MR Alb-Ptp1b
-/-
 mice (n=5). Fasting serum insulin levels were measured in (f) 
female CON
 
Ptp1b
fl/fl 
(n=8), MR Ptp1b
fl/fl
 (n=8) and MR Alb-Ptp1b
-/-
 mice (n=8) and (g) male CON 
Ptp1b
fl/fl 
(n=5), MR Ptp1b
fl/fl
 (n=5) and MR Alb-Ptp1b
-/-
 mice (n=5). Data are represented as mean ± 
s.e.m. White circles/bars, CON
 
Ptp1b
fl/fl 
; grey squares/bars, MR Ptp1b
fl/fl
; black triangles/bars, MR 
Alb-Ptp1b
-/-
. Data were analysed by repeated measures two-way ANOVA with Bonferroni multiple 
comparison post hoc tests or one-way ANOVA with Tukey's multiple comparison post hoc test.* MR 
Alb-Ptp1b
-/-
 and MR Ptp1b
fl/fl
 mice significantly different to CON
 
Ptp1b
fl/fl 
mice (p<0.05). $ MR Alb-
Ptp1b
-/-
 mice significantly different to MR Ptp1b
fl/fl
 mice (p<0.05). # MR Alb-Ptp1b
-/-
 mice 
significantly different to CON
 
Ptp1b
fl/fl 
mice (p<0.05). 
 
Fig. 5 Lipid homeostasis. Fasting serum leptin levels were measured in (a) female CON
 
Ptp1b
fl/fl 
(n=8), MR Ptp1b
fl/fl
 (n=8) and MR Alb-Ptp1b
-/-
 mice (n=8) and (b) male CON
 
Ptp1b
fl/fl
 (n=4), MR 
Ptp1b
fl/fl
 (n=4) and MR Alb-Ptp1b
-/-
 mice (n=5). Fasting serum NEFA levels were measured in (c) 
female CON
 
Ptp1b
fl/fl 
(n=8), MR Ptp1b
fl/fl
 (n=8) and MR Alb-Ptp1b
-/-
 mice (n=8) and (d) male CON
 
Ptp1b
fl/fl 
(n=5), MR Ptp1b
fl/fl
 (n=5) and MR Alb-Ptp1b
-/-
 mice (n=5). Fasting serum triacylglycerol 
levels were measured in (e) female CON
 
Ptp1b
fl/fl 
(n=8), MR Ptp1b
fl/fl
 (n=8) and MR Alb-Ptp1b
-/-
 mice 
(n=8) and (f) male CON
 
Ptp1b
fl/fl 
(n=5), MR Ptp1b
fl/fl
 (n=5) and MR Alb-Ptp1b
-/-
 mice (n=5). Hepatic 
gene expression in female CON
 
Ptp1b
fl/fl
 (n=5), MR Ptp1b
fl/fl
 (n=4) and MR Alb-Ptp1b
-/-
 mice (n=6). 
). Data are represented as mean ± s.e.m. White bars, CON
 
Ptp1b
fl/fl 
; grey bars, MR Ptp1b
fl/fl
; black 
bars, MR Alb-Ptp1b
-/-
. Data were analysed by one-way ANOVA with Tukey's multiple comparison 
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post hoc test.* MR Alb-Ptp1b
-/-
 and MR Ptp1b
fl/fl
 mice significantly different to CON
 
Ptp1b
fl/fl 
mice 
(p<0.05). 
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